Uncategorized

Next-generation obesity drugs are on the horizon: The success of semaglutide and tirzepatide have fueled the development of over 100 anti-obesity drug candidates, with an anticipated market value exceeding $100 billion by 2030. These emerging drugs, including bimagrumab to prevent muscle loss and retatrutide targeting multiple hormone receptors for enhanced weight loss, aim to improve efficacy and tolerability and address current treatment limitations.

The US Food and Drug Administration (FDA) announced plans to implement AI tools throughout the Agency to assist in conducting scientific reviews following the successful completion of a pilot program that incorporated generative AI into reviews.

The United States Food and Drug Administration (FDA) announced it will expand its effort to conduct unannounced inspections of foreign manufacturing facilities that produce medical products and foods.

Study with monkeys uncovers why people choke under pressure: A recent study with monkeys explores the phenomenon of “choking” under pressure, finding that heightened anxiety can interfere with brain function. The findings suggest that recreating “optimal” neural signatures could help humans enhance performance in high-pressure situations.

Researchers engineer toxic male mosquitoes: Researchers have developed a method to control mosquito populations by genetically engineering male mosquitoes to produce venom proteins from spiders and sea anemones, which are injected into females during mating to reduce their lifespan. The “toxic male technique” could quickly suppress outbreaks of diseases such as dengue fever and Zika without extensive insecticide use, according to a study in Nature Communications.

FDA urged to collaborate with EMA (European Medicines Agency) to accelerate rare disease drug approvals: A report by the National Academies of Sciences, Engineering and Medicine recommends that the FDA enhance transparency and collaborate with the European Medicines Agency to systematically review past rare disease drug applications and regulatory decision-making to expedite approvals. The report advises the EMA and FDA to create a continuously updated public database for these results, and also recommends Congress remove the Pediatric Research Equity Act orphan exemption.

CBD products truly are everywhere these days. From gummies to topical creams and now tampons, it seems there is no limit to where this trendy compound might appear. However, a recent FDA Warning Letter to Anne’s Daye (dba Tampon Innovations) serves as a blunt reminder to medical device manufacturers: you cannot just lace your products with CBD and expect FDA to be mellow about it. CBD products truly are everywhere these days.

The US Food and Drug Administration (FDA), in early January 2025, published a much-anticipated guidance on developing and managing medical devices with artificial intelligence (AI). The Agency recommends taking a total product lifecycle (TPLC) approach to the products to ensure they meet their expectations for safety and efficacy.

FDA’s unpopular LDT final rule could meet its maker when the president-elect hits the oval office, but how is he most likely to upend it?

Officials at the United States Food and Drug Administration (FDA) are reportedly planning to reduce the number of routine inspections carried out by the Office of Inspections and Investigations (OII) after last week’s layoffs due to steep layoffs week in support staff, according to a report late last week by CBS News.